Estrella Immunopharma, Inc. (ESLA)Healthcare | Biotechnology | EmeryVille, United States | NasdaqCM
0.88 USD
-0.06
(-6.851%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.88 |
Hot Take ↕ | July 11, 2026, 3:16 a.m. EDT
The immediate outlook remains deeply bearish as the stock trades significantly below its 50-day and 200-day moving averages, indicating persistent selling pressure and a lack of technical support. While a recent oral presentation of Phase 1 data offers a potential catalyst, the underlying financial reality is dire: the company reports negative book value, massive operating cash outflows, and a trailing EPS of -$0.34, signaling a business that is currently burning capital without generating returns. The long-term investment case is effectively nonexistent; the asset has suffered a catastrophic 91% decline over the last three years, with the most recent annual performance showing another sharp drop of nearly 35%. This multi-year structural deterioration suggests the market has already priced in the failure of the current business model, rendering any 'value' argument moot. Furthermore, there is no dividend income to offset these risks, as the company has no history of payouts. Investors should view this as a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL_110 ✓ | 0.172953 |
| AutoTheta | 0.322749 |
| AutoARIMA | 0.363044 |
| AutoETS | 0.363930 |
| MSTL | 0.376555 |
Forecast horizon: 60 days | Selected: MSTL_110
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 2.12 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.142 |
| Excess Kurtosis | -0.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 37,680,768 |
| Forward P/E | -2.74 |
| Beta | 0.86 |
| Website | https://www.estrellabio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.047457576 |
| Address1 | 5,858 Horton Street |
| Address2 | Suite 370 |
| All Time High | 33.0 |
| All Time Low | 0.63 |
| Ask | 1.17 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 47,060 |
| Average Daily Volume3 Month | 39,957 |
| Average Volume | 39,957 |
| Average Volume10Days | 47,060 |
| Beta | 0.858 |
| Bid | 1.14 |
| Bid Size | 1 |
| Book Value | -0.124 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.8756 |
| Current Ratio | 0.242 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.97 |
| Day Low | 0.8646 |
| Display Name | Estrella Immunopharma |
| Ebitda Margins | 0.0 |
| Enterprise Value | 35,753,368 |
| Eps Current Year | -0.39 |
| Eps Forward | -0.32 |
| Eps Trailing Twelve Months | -0.34 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.12604 |
| Fifty Day Average Change | -0.25044 |
| Fifty Day Average Change Percent | -0.22240773 |
| Fifty Two Week Change Percent | 4.7457576 |
| Fifty Two Week High | 3.15 |
| Fifty Two Week High Change | -2.2744002 |
| Fifty Two Week High Change Percent | -0.7220318 |
| Fifty Two Week Low | 0.78 |
| Fifty Two Week Low Change | 0.09560001 |
| Fifty Two Week Low Change Percent | 0.12256412 |
| Fifty Two Week Range | 0.78 - 3.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,631,626,200,000 |
| Float Shares | 14,110,063 |
| Forward Eps | -0.32 |
| Forward P E | -2.73625 |
| Free Cashflow | -2,719,652 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.60605997 |
| Held Percent Institutions | 0.12149999 |
| Implied Shares Outstanding | 43,034,228 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc. |
| Long Name | Estrella Immunopharma, Inc. |
| Market | us_market |
| Market Cap | 37,680,768 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_1802952199 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -13,251,265 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 39,888,425 |
| Number Of Analyst Opinions | 1 |
| Open | 0.9084 |
| Operating Cashflow | -8,017,708 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 510 318 9098 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.8756 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 0.94 |
| Price Eps Current Year | -2.2451282 |
| Price Hint | 4 |
| Price To Book | -7.0612903 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.216 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0644 |
| Regular Market Change Percent | -6.85107 |
| Regular Market Day High | 0.97 |
| Regular Market Day Low | 0.8646 |
| Regular Market Day Range | 0.8646 - 0.97 |
| Regular Market Open | 0.9084 |
| Regular Market Previous Close | 0.94 |
| Regular Market Price | 0.8756 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 21,981 |
| Return On Assets | -2.7145998 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 43,034,228 |
| Shares Percent Shares Out | 0.0021 |
| Shares Short | 89,082 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 82,599 |
| Short Name | Estrella Immunopharma, Inc. |
| Short Percent Of Float | 0.0053 |
| Short Ratio | 2.1 |
| Source Interval | 15 |
| State | CA |
| Symbol | ESLA |
| Target High Price | 12.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 12.0 |
| Target Median Price | 12.0 |
| Total Cash | 1,927,404 |
| Total Cash Per Share | 0.045 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.34 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.43008 |
| Two Hundred Day Average Change | -0.5544801 |
| Two Hundred Day Average Change Percent | -0.3877266 |
| Type Disp | Equity |
| Volume | 21,981 |
| Website | https://www.estrellabio.com |
| Zip | 94,608 |